Cancer Research and Treatment

Original Articles

General

Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial: Yaewon Yang, Jang-Hee Hahn, Min Seo Kim, Minkwan Jo, Yong-Pyo Lee, Hongsik Kim, Hee Kyung Kim, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2024;56(4):1050-1057. Published online June 5, 2024; DOI: https://doi.org/10.4143/crt.2024.080

Abstract PDF Supplementary Material PubReader ePub: Purpose
Hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR) are relatively common toxicities that interfere with the quality of life (QoL) of patients with cancer. Anti-inflammatory tripeptide cream (ATPC) is a complex formulation of anti-inflammatory tripeptides, the CD99-agonist Binterin and the Wnt-antagonist Winhibin. The present study aimed to assess the therapeutic effects of ATPC in HFS/HFSR associated with anticancer drugs.
Materials and Methods
This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to 9 weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
Results
Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
Conclusion
Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.

1,473 View
156 Download

Gastrointestinal cancer

A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10): Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi; Cancer Res Treat. 2023;55(4):1250-1260. Published online May 25, 2023; DOI: https://doi.org/10.4143/crt.2023.333

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.
Materials and Methods
Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.

Citations

Citations to this article as recorded by

A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort
Ziming Zhao, Erxun Dai, Bao Jin, Ping Deng, Zulihaer Salehebieke, Bin Han, Rongfan Wu, Zhaowu Yu, Jun Ren
Clinical and Translational Oncology.2024;[Epub] CrossRef

3,457 View
288 Download
1 Web of Science
1 Crossref

Lung and Thoracic cancer

Histologic Changes in Non–Small Cell Lung Cancer under Various Treatments: A Comparison of Histology and Mutation Status in Serial Samples: Chang Gok Woo, Seung-Myoung Son, Ho-Chang Lee, Hye Sook Han, Ki Hyeong Lee, Dohun Kim, Eung-Gook Kim, Ok-Jun Lee; Cancer Res Treat. 2022;54(3):737-743. Published online September 24, 2021; DOI: https://doi.org/10.4143/crt.2021.773

Abstract PDF Supplementary Material PubReader ePub

Purpose
Histologic change is a resistant mechanism in lung cancer. The most common histological change is the switch from adenocarcinoma (AdenoCa) to small cell carcinoma (SCC) against to tyrosine kinase inhibitors (TKI). However, it is not clear whether other treatment modalities are involved in the histologic changes.
Materials and Methods
We investigated histological changes in eight cases, after various treatments, and compared the molecular profiles between primary tumors and changed tumors using exome sequencing where tissue was available.
Results
Three cases of AdenoCa that were changed into SCC retained the initial mutations after TKI and/or surgical treatment. After treatment with TKI and immunotherapy, an EGFR (epidermal growth factor receptor)-mutant AdenoCa changed to squamous cell carcinoma (SqCa). SqCa in a patient treated with surgery was changed into combined AdenoCa and SqCa. These two cases showed the same genetic variations between the two distinct non–small cell carcinomas (NSCC). Three patients experienced two histologic changes, which the changed tumors returned to its original subtype or changed to a combined tumor after treatments. Four cases showed combined histology in the first or second change.
Conclusion
The histology of NSCC can be changed to a single pattern or combined subtypes after various treatment modalities, and the phenotypic changes seem not fixed. Therefore, additional morphologic changes may occur regardless of their genetic status and types of treatments. To refine the new treatment strategy, consecutive repeated biopsies in progressive disease or recurrent tumor are necessary.

Citations

Citations to this article as recorded by

Using ex vivo bioengineered lungs to model pathologies and screening therapeutics: A proof‐of‐concept study
Mohammadali Ahmadipour, Jorge Castilo Prado, Benyamin Hakak‐Zargar, Malik Quasir Mahmood, Ian M. Rogers
Biotechnology and Bioengineering.2024; 121(10): 3020. CrossRef
Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome
Shuo Li, Wenyuan Li, Bin Liu, Kostyantyn Krysan, Steven M. Dubinett
Cancer Research Communications.2024; 4(7): 1738. CrossRef
Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases
Alessandro Bonis, Andrea Dell’Amore, Vincenzo Verzeletti, Luca Melan, Giovanni Zambello, Chiara Nardocci, Giovanni Maria Comacchio, Federica Pezzuto, Fiorella Calabrese, Federico Rea
Journal of Clinical Medicine.2023; 12(4): 1411. CrossRef
Gene‐level dissection of chromosome 3q locus amplification in squamous cell carcinoma of the lung using the nCounter assay
Taesung Jeon, Uk Jeen Oh, Jaeyoung Min, Chungyeul Kim
Thoracic Cancer.2023; 14(26): 2635. CrossRef
Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience
Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi
Cancer Research and Treatment.2023; 55(4): 1181. CrossRef
Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx® Digital Spatial Profiler
Sharia Hernandez, Rossana Lazcano, Alejandra Serrano, Steven Powell, Larissa Kostousov, Jay Mehta, Khaja Khan, Wei Lu, Luisa M. Solis
Frontiers in Oncology.2022;[Epub] CrossRef

6,442 View
208 Download
7 Web of Science
6 Crossref

The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study: Jihyun Kwon, So Young Kim, Kyoung Eun Yeob, Hye Sook Han, Ki Hyeong Lee, Dong Wook Shin, Yeon-Yong Kim, Jong Heon Park, Jong Hyock Park; Cancer Res Treat. 2020;52(1):1-9. Published online April 22, 2019; DOI: https://doi.org/10.4143/crt.2018.702

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to determine whether the diagnosis, treatment approach, and prognosis of multiple myeloma (MM) vary according to the presence and type of disability.
Materials and Methods
Demographic, socioeconomic, and medical data were obtained from the National Disability Database, the Korean Central Cancer Registry, and the Korean National Health Insurance claims database. An age- and sex-matched cohort was established using a 1:3 ratio constituted with 2,776,450 people with disabilities and 8,329,350 people without disabilities. Adult patients diagnosed with MM were subsequently selected from this cohort. Disabilities were categorized as physical, communication, intellectual or psychological, and affecting the major internal organs.
Results
The cohort included 4,090 patients with MM, with a significantly lower rate per 100,000 persons among people with disabilities than among people without disabilities (29.1 vs. 39.4, p < 0.001). People with disabilities were more likely to undergo dialysis treatment at the time of diagnosis (16.3% vs. 10.0%, p < 0.001), but were less likely to undergo autologous stem cell transplantation (37.5% vs. 43.7%, p=0.072). This trend was more evident among patients with intellectual or psychological disabilities. The median overall survival among patients with disabilities was significantly shorter than that among patients without disabilities (36.8 months vs. 51.2 months, p < 0.001).
Conclusion
In Korea, people with disabilities generally have a lower rate of MM diagnosis, receive less intensive treatment, and have a lower survival rate than people without disabilities.

Citations

Citations to this article as recorded by

Case report: IORT as an alternative treatment option for breast cancer patients with difficulty staying still
Fardeen Bhimani, Maureen McEvoy, Yu Chen, Anjuli Gupta, Jessica Pastoriza, Shani Fruchter, Zachary C. Bitan, Wolfgang A. Tomé, Keyur Mehta, Jana Fox, Sheldon Feldman
Frontiers in Oncology.2024;[Epub] CrossRef
The Korea National Disability Registration System
Miso Kim, Wonyoung Jung, So Young Kim, Jong Hyock Park, Dong Wook Shin
Epidemiology and Health.2023; 45: e2023053. CrossRef
Do people with disabilities experience disparities in cancer care? A systematic review
Irene Tosetti, Hannah Kuper, Sina Azadnajafabad
PLOS ONE.2023; 18(12): e0285146. CrossRef
Cancer detection, diagnosis, and treatment for adults with disabilities
Lisa I Iezzoni
The Lancet Oncology.2022; 23(4): e164. CrossRef
Disparities in All-Cause Mortality in Older Patients with Colorectal Cancer According to Disability Status: A Nationwide Analysis
Woo-Ri Lee, Kyu-Tae Han, Mingee Choi, Woorim Kim
Current Oncology.2022; 29(10): 7430. CrossRef
Disparities in prostate cancer diagnosis, treatment, and survival among men with disabilities: Retrospective cohort study in South Korea
Dong Wook Shin, Jinsung Park, Kyoung Eun Yeob, Seok Jung Yoon, Soong-nang Jang, So Young Kim, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Disability and Health Journal.2021; 14(4): 101125. CrossRef
Disparities in the Diagnosis, Treatment, and Survival Rate of Cervical Cancer among Women with and without Disabilities
Jin Young Choi, Kyoung Eun Yeob, Seung Hwa Hong, So Young Kim, Eun-Hwan Jeong, Dong Wook Shin, Jong Heon Park, Gil-won Kang, Hak Soon Kim, Jong Hyock Park, Ichiro Kawachi
Cancer Control.2021;[Epub] CrossRef
Disparities in the Diagnosis and Treatment of Gastric Cancer in Relation to Disabilities
Hyoung Woo Kim, Dong Wook Shin, Kyoung Eun Yeob, In Young Cho, So Young Kim, Seon Mee Park, Jong Heon Park, Jong Hyock Park, Ichiro Kawachi
Clinical and Translational Gastroenterology.2020; 11(10): e00242. CrossRef

9,412 View
365 Download
7 Web of Science
8 Crossref

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study: So-Yeon Jeon, Hye Sook Han, Woo Kyun Bae, Moo-Rim Park, Hyeok Shim, Sang-Cheol Lee, Se-Il Go, Hwan Jung Yun, Yong-Jin Im, Eun-Kee Song; Cancer Res Treat. 2019;51(1):90-97. Published online February 27, 2018; DOI: https://doi.org/10.4143/crt.2017.577

Abstract PDF PubReader ePub

Purpose
Data on the efficacy of olanzapine in patients receiving moderately emetogenic chemotherapy (MEC) are limited. This study aimed to evaluate and compare the efficacy of olanzapine versus placebo in controlling nausea and vomiting in patients receiving MEC.
Materials and Methods
We conducted a randomized, double-blind, placebo-controlled study to determine whether olanzapine can reduce the frequency of chemotherapy-induced nausea and vomiting (CINV) and improve the quality of life (QOL) in patients receiving palonosetron and dexamethasone as prophylaxis for MEC-induced nausea and vomiting. The primary end point was complete response for the acute phase (0-24 hours after chemotherapy). The secondary end points were complete response for the delayed (24-120 hours) and overall phase (0-120 hours), proportion of significant nausea (visual analogue scale ≥ 25 mm), use ofrescue medications, and effect on QOL.
Results
Fifty-six patients were randomized to the olanzapine (n=29) and placebo (n=27) groups. Complete response rates were not significantly different between the olanzapine and placebo groups in the acute (96.5% vs. 88.0%, p=0.326), delayed (69.0% vs. 48.0%, p=0.118), and overall phases (69.0% vs. 48.0%, p=0.118). However, the percentage of patients with significant nausea (17.2% vs. 44.0%, p=0.032) and the use of rescue medications (0.03±0.19 vs. 1.88±2.88, p=0.002) were lower in the olanzapine group than in the placebo. Furthermore, the olanzapine group demonstrated better QOL (p=0.015).
Conclusion
Olanzapine combined with palonosetron and dexamethasone significantly improved QOL and vomiting control among previously untreated patients receiving MEC, although the efficacy was limited to the reduction of the frequency of CINV.

Citations

Citations to this article as recorded by

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
Samantha K. F. Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C. Y. Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J. Gralla, Ter
Supportive Care in Cancer.2024;[Epub] CrossRef
A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy
Jing Shen, Juan Zhao, Gaowa Jin, Hui Li, Ying Jiang, Yungaowa Wu, Jiali Gao, Feng Chen, Jiaxuan Li, Wenjuan Wang, Quanfu Li
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Health-Related Quality of Life and Economic Analysis of Olanzapine Versus Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Malaysia
Nurul Suhaida Badarudin, Noraida Mohamed Shah, Nurul Ain Mohd Tahir, Azmi Nor Mohd Farez Ahmat, Fuad Ismail, Farida Islahudin, Suhana Yusak, Syahir Muhammad, Kamarun Neasa Begam Mohd Kassim
Value in Health Regional Issues.2024; 44: 101028. CrossRef
Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy
Vikas Ostwal, Anant Ramaswamy, Sarika Mandavkar, Prabhat Bhargava, Deepali Naughane, Sharon Flavia Sunn, Sujay Srinivas, Akhil Kapoor, Bal Krishna Mishra, Anuj Gupta, Bipinesh Sansar, Vikash Pal, Aparajita Pandey, Avinash Bonda, Indraja Siripurapu, Vamshi
JAMA Network Open.2024; 7(8): e2426076. CrossRef
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clin
Kazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako
International Journal of Clinical Oncology.2024; 29(12): 1785. CrossRef
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
Kazuhisa Nakashima, Saki Harashima, Rena Kaneko, Ryuhei Tanaka, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Eriko Satomi, Masayuki Takeda, Takako Eguchi Nakajima, Naoki
International Journal of Clinical Oncology.2024;[Epub] CrossRef
Can olanzapine preserve life quality in cancer patients undergoing abdominal radiation therapy?
Meenu Vijayan, Sherin Joseph, Haridas M Nair, Debnarayan Dutta, M.P. Narmadha
Medical Hypotheses.2023; 171: 111014. CrossRef
Chemotherapy: how to reduce its adverse effects while maintaining the potency?
Brianna, Sau Har Lee
Medical Oncology.2023;[Epub] CrossRef
The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
Aziz Eghbali, Tahereh Bagherloo, Ali Ghasemi, Roghayeh R. Afzal, Aygin Eghbali, Kazem Ghaffari
Advanced Biomedical Research.2023;[Epub] CrossRef
Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka
Journal of Pharmaceutical Health Care and Sciences.2023;[Epub] CrossRef
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
Rony Dev, Linda L. Zhong, Abdulrazzak Zarifa, Aya A. Albittar, Laura Rubin, Suyu Liu, Timothy A. Yap, Shalini Dalal, David Hui, Daniel D. Karp, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Aung Naing
Investigational New Drugs.2022; 40(1): 124. CrossRef
Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis
Priya Patel, Paula D. Robinson, Nora Wahib, Patrick Cheung, Thomas Wong, Sandra Cabral, Arden Parker, Marie Cohen, Katie Devine, Paul Gibson, Mark T. Holdsworth, Eloise Neumann, Andrea Orsey, Robert Phillips, Daniela Spinelli, Jennifer Thackray, Marianne
Supportive Care in Cancer.2022; 30(11): 8855. CrossRef
Ջոակինո Ռոսինիի «Stabat Mater»-ը Հովհաննես Չեքիջյանի մեկնաբանությամբ (նվիրվում է Ռոսինիի «Stabat Mater»-ի ստեղծման 180-ամյակին և Հայաստանի ազգային ակադեմիական երգչախմբի հիմնադրման 85-ամյակին)
Աննա Ասատրյան
Journal of Art Studies.2022; : 79. CrossRef
Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
Maurice J.D.L. van der Vorst, Elisa C. Toffoli, Marlien Beusink, Myra E. van Linde, Theo van Voorthuizen, Saskia Brouwer, Annette A. van Zweeden, Suzan Vrijaldenhoven, Johan C. Berends, Johannes Berkhof, Henk M.W. Verheul
The Oncologist.2021; 26(1): e173. CrossRef
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
Ronald Chow, Jørn Herrstedt, Matti Aapro, Leonard Chiu, Henry Lam, Elizabeth Prsic, Michael Lock, Carlo DeAngelis, Rudolph M. Navari
Supportive Care in Cancer.2021; 29(7): 3439. CrossRef
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
Junichi Nishimura, Akiko Hasegawa, Toshihiro Kudo, Tomoyuki Otsuka, Masayoshi Yasui, Chu Matsuda, Naotsugu Haraguchi, Hajime Ushigome, Nozomu Nakai, Tomoki Abe, Hisashi Hara, Naoki Shinno, Kei Asukai, Shinichiro Hasegawa, Daisaku Yamada, Keijiro Sugimura,
Scientific Reports.2021;[Epub] CrossRef
The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis
Dong-Yang Wang, Yi Chen, You Zhang, Ying-Qiang Shen
Frontiers in Oncology.2021;[Epub] CrossRef
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
Winnie Yeo, Thomas KH. Lau, Leung Li, Kwai Tung Lai, Elizabeth Pang, Maggie Cheung, Vicky TC. Chan, Ashley Wong, Winnie MT. Soo, Vanessa TY. Yeung, Teresa Tse, Daisy CM. Lam, Eva WM. Yeung, Kim PK. Ng, Nelson LS. Tang, Macy Tong, Joyce JS. Suen, Frankie K
The Breast.2020; 50: 30. CrossRef
RETRACTED ARTICLE: Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation
Kifayat Ullah Khan, Naveed Akhtar, Muhammad Usman Minhas
AAPS PharmSciTech.2020;[Epub] CrossRef
Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study

Xuan Wu, Jingxun Wu, Gangling Tong, Boran Cheng, Minhua Chen, Shaokang Yu, Lirui He, Zhu Li, Shubin Wang
Cancer Management and Research.2020; Volume 12: 6575. CrossRef
Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
So Rae Lee, Su Min Kim, Min Young Oh, Jae Min Lee
Children.2020; 7(9): 140. CrossRef
Olanzapine: The Game-Changer “Antiemetic”
Manikandan Dhanushkodi
Indian Journal of Medical and Paediatric Oncology.2019; 40(02): 274. CrossRef

9,305 View
494 Download
24 Web of Science
22 Crossref

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors: Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han; Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017; DOI: https://doi.org/10.4143/crt.2017.378

Abstract PDF PubReader ePub

Purpose
Malignant pleural effusions (MPEs) are often observed in lung cancer, particularly adenocarcinoma. The aim of this study was to investigate epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma-associated MPEs (LA-MPEs) and its correlation with efficacy of EGFR tyrosine kinase inhibitor (TKI) therapy.
Materials and Methods
Samples comprised 40 cell blocks of pathologically-confirmed LA-MPEs collected before the start of EGFR TKI therapy. EGFR mutation status was re-evaluated by peptide nucleic acid clamping and the clinical outcomes of EGFR TKI‒treated patients were analyzed retrospectively.
Results
EGFR mutations were detected in 72.5% of LA-MPE cell blocks (29/40). The median progression-free survival for patients with EGFR mutations in LA-MPEs was better than that for patients with wild-type EGFR (7.33 months vs. 2.07 months; hazard ratio, 0.486; 95% confidence interval, 0.206 to 1.144; p=0.032). The objective response rate (ORR) of 26 patients with EGFR mutations in LA-MPEs among the 36 patients with measurable lesions was 80.8%, while the ORR of the 10 patients with wild-type EGFR in LA-MPEs was 10% (p < 0.001). Among the 26 patients with EGFR mutations in LA-MPEs, the ORR of target lesions and LA-MPEs were 88.5% and 61.5%, respectively (p=0.026).
Conclusion
EGFR mutation status in cell blocks of LA-MPEs confirmed by pathologic diagnosis is highly predictive of EGFR TKI efficacy. For patients with EGFR mutations in LA-MPEs, the response to EGFR TKIs seems to be worse for pleural effusions than for solid tumors.

Citations

Citations to this article as recorded by

Cancer‐associated fibroblast‐derived colony‐stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis
Yutang Huang, Xiaoqing Wang, Chunjie Wen, Jingchan Wang, Honghao Zhou, Lanxiang Wu
MedComm.2024;[Epub] CrossRef
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, Ashley Gillson, Daniel Stollery, Pen Li
Respiratory Medicine.2023; 206: 107093. CrossRef
Malignant pleural effusion diagnosis and therapy
Liangliang Yang, Yue Wang
Open Life Sciences.2023;[Epub] CrossRef
Failure pattern and radiotherapy exploration in malignant pleural effusion non-small cell lung cancer treated with targeted therapy
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Frontiers in Oncology.2023;[Epub] CrossRef
Impact of thoracic tumor radiotherapy on survival in non‐small‐cell lung cancer with malignant pleural effusion treated with targeted therapy: Propensity score matching study
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Haijie Jin, Huiqin Li, Bing Lu
Cancer Medicine.2023; 12(14): 14949. CrossRef
EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery
Toshiya Fujiwara, Kazuhiko Shien, Motoki Matsuura, Junichi Soh, Hiromasa Yamamoto, Soshi Takao, Yuho Maki, Tsuyoshi Ueno, Ryujiro Sugimoto, Ken Suzawa, Mikio Okazaki, Hiroyuki Tao, Makio Hayama, Masafumi Kataoka, Yoshifumi Sano, Hidetoshi Inokawa, Motohir
Annals of Surgical Oncology.2023; 30(11): 6697. CrossRef
Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef
Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
Xinyang Du, Hua Bai, Zhijie Wang, Jianchun Daun, Zheng Liu, Jiachen Xu, Geyun Chang, Yixiang Zhu, Jie Wang
Thoracic Cancer.2022; 13(9): 1289. CrossRef
Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non‐small‐cell lung cancer
Wei Zhang, Wenjuan Han, Bo Yu, Xin Zhao, Gaojun Lu, Wendy Wu, Yi Zhang
Thoracic Cancer.2022; 13(11): 1642. CrossRef
Management of Malignant Pleural Effusion: Where Are We Now?
Julien Guinde, Hervé Dutau, Philippe Astoul
Seminars in Respiratory and Critical Care Medicine.2022; 43(04): 559. CrossRef
Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Cancer Management and Research.2022; Volume 14: 3347. CrossRef
The impact of smoking status on the progression‐free survival of non‐small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta‐analysis
Xinyi Li, Cong Huang, Xiaohui Xie, Ziyang Wu, Xia Tian, Yibo Wu, Xin Du, Luwen Shi
Journal of Clinical Pharmacy and Therapeutics.2021; 46(2): 256. CrossRef
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen S
Chest.2021; 159(3): 1256. CrossRef
Advances in pleural infection and malignancy
Eihab O. Bedawi, Julien Guinde, Najiib M. Rahman, Philippe Astoul
European Respiratory Review.2021; 30(159): 200002. CrossRef
Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
Cancers.2021; 13(11): 2798. CrossRef
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer
Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, Aoi Kuroda, Hideki Terai, Keita Masuzawa, Taro Shinozaki, Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima
Cancer Management and Research.2021; Volume 13: 7497. CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología.2020; 56(7): 465. CrossRef
Current applications of molecular testing on body cavity fluids
Daniel Pinto, Fernando Schmitt
Diagnostic Cytopathology.2020; 48(9): 840. CrossRef
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
Jianqiang Li, Xingliang Li, Wenxian Wang, Yang Shao, Yiping Zhang, Zhengbo Song
Translational Oncology.2020; 13(8): 100784. CrossRef
Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations
Ning Liu, Min Yu, Tao Yin, Yong Jiang, Xuelian Liao, Jie Tang, Yanying Li, Diyuan Qin, Dan Li, Yongsheng Wang
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
LENT Score: Predicting the Survival of Malignant Pleural Effusion – A Prospective Study of Three Years
Sara Raimundo, Ana Isabel Loureiro, Fortunato Vieira, Ana Fernandes
Archivos de Bronconeumología (English Edition).2020; 56(7): 465. CrossRef
Recent Developments in the Management of Malignant Pleural Effusions: a Narrative Review
Clifford E. Coile, Jessie G. Harvey, Michal Senitko
Current Pulmonology Reports.2020; 9(4): 164. CrossRef
Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
Yi Yao, Min Peng, Qinglin Shen, Qinyong Hu, Hongyun Gong, Qingqing Li, Zhongliang Zheng, Bin Xu, Yingge Li, Yi Dong
Thoracic Cancer.2019; 10(2): 193. CrossRef
Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef
Novel insights into the systemic treatment of lung cancer malignant pleural effusion
Claire Tissot, Pierre Gay, Clément Brun, Marios E. Froudarakis
The Clinical Respiratory Journal.2019; 13(3): 131. CrossRef
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma
Momin T. Siddiqui, Fernando Schmitt, Andrew Churg
Journal of the American Society of Cytopathology.2019; 8(6): 352. CrossRef

10,017 View
279 Download
35 Web of Science
26 Crossref

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine: Keun-Wook Lee, Bum Jun Kim, Mi-Jung Kim, Hye Sook Han, Jin Won Kim, Young Iee Park, Sook Ryun Park; Cancer Res Treat. 2017;49(3):706-716. Published online October 18, 2016; DOI: https://doi.org/10.4143/crt.2016.216

Abstract PDF PubReader ePub

Purpose
This study evaluated the re-challenge of S-1 or cisplatin in combination with docetaxel in metastatic gastric cancer (MGC) that had progressed on a cisplatin plus either S-1 or capecitabine regimen.
Materials and Methods
Patients with progressive disease after first-line cisplatin plus S-1 or capecitabine were randomized to receive 3-week cycles of docetaxel 75 mg/m² intravenously (IV) on D1 (D), docetaxel 60 mg/m² IV plus cisplatin 60 mg/m² IV on D1 (DC), or docetaxel 60 mg/m² IV D1 plus oral S-1 30 mg/m² twice a day on D1-14 (DS).
Results
Seventy-two patients were randomized to the D (n=23), DC (n=24), or DS (n=25) group. The confirmed response rate was 4.3% (95% confidence interval [CI], 0% to 12.6%), 4.3% (95% CI, 0% to 12.6%), and 8.7% (95% CI, 0% to 20.2%) for the D, DC, and DS groups, respectively. Compared to the D arm, the DS arm had a better progression-free survival (2.7 months vs. 1.3 months, p=0.034) without any deterioration in safety or quality of life, whereas the DC arm had a similar progression-free survival (1.8 months vs. 1.3 months, p=0.804) and poorer overall survival (5.6 months vs. 10.0 months, p=0.035).
Conclusion
A re-challenge with S-1, but not cisplatin, in combination with docetaxel has potential anticancer benefits over docetaxel alone in MGC with progression after prior cisplatin plus S-1 or capecitabine.

Citations

Citations to this article as recorded by

Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab
Yulia D’yachkova, Astra M. Liepa, Rajat Goel, Veronika Earley-Valovic, Abby Paine, Palvi Gupta, Kaisa Taipale
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Efficacy and safety of docetaxel plus S-1-based therapy in gastric cancer: a quantitative evidence synthesis of randomized controlled trials
Hui-Fen Lv, Li-Feng Qin, Rui-Zhi Ran, Xue-Ping Jiang, Fang-Yu Zhao, Bo Li
Frontiers in Pharmacology.2024;[Epub] CrossRef
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis
Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi
Journal of Gastrointestinal Cancer.2023; 54(4): 1031. CrossRef
Platinum-Based Chemotherapy ‘Rechallenge’ in Advanced Non-ovarian Solid Malignancies
J. Hack, S.J. Crabb
Clinical Oncology.2022; 34(8): e329. CrossRef
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences
Alison Rowsell, Samantha C. Sodergren, Vassilios Vassiliou, Anne-Sophie Darlington, Marianne G. Guren, Bilal Alkhaffaf, Chantelle Moorbey, Kristopher Dennis, Mitsumi Terada
Gastric Cancer.2022; 25(4): 665. CrossRef
Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology
Elisabeth Coart, Everardo D. Saad
Expert Review of Precision Medicine and Drug Development.2021; 6(4): 271. CrossRef
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Daniel V. Catenacci, Joseph Chao, Kei Muro, Salah Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem
The Oncologist.2021; 26(10): e1704. CrossRef
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi
Medical Council.2019; (10): 100. CrossRef
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis
Bo Li, Lian Chen, Hong-Liang Luo, Feng-Ming Yi, Yi-Ping Wei, Wen-Xiong Zhang
World Journal of Clinical Cases.2019; 7(5): 600. CrossRef
A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer
Dan Zhang, Jia-Rui Wu, Xiao-Jiao Duan, Kai-Huan Wang, Yi Zhao, Meng-Wei Ni, Shu-Yu Liu, Xiao-Meng Zhang, Bing Zhang
Frontiers in Pharmacology.2019;[Epub] CrossRef
Systemic therapy for previously treated advanced gastric cancer: A systematic review and network meta-analysis
Ji Cheng, Ming Cai, Xiaoming Shuai, Jinbo Gao, Guobin Wang, Kaixiong Tao
Critical Reviews in Oncology/Hematology.2019; 143: 27. CrossRef
Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis
Jessy Joy van Kleef, Emil ter Veer, Héctor G van den Boorn, Sandor Schokker, Lok Lam Ngai, Mariska J Prins, Nadia Haj Mohammad, Lonneke V van de Poll-Franse, Aeilko H Zwinderman, Martijn G H van Oijen, Mirjam A G Sprangers, Hanneke W M van Laarhoven
JNCI: Journal of the National Cancer Institute.2019;[Epub] CrossRef

10,609 View
358 Download
13 Web of Science
13 Crossref

A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients: Yusook Jeong, Hye Sook Han, Hyo Duk Lee, Jiyoul Yang, Jiwon Jeong, Moon Ki Choi, Jihyun Kwon, Hyun-Jung Jeon, Tae-Keun Oh, Ki Hyeong Lee, Seung Taik Kim; Cancer Res Treat. 2016;48(4):1429-1437. Published online February 29, 2016; DOI: https://doi.org/10.4143/crt.2015.464

Abstract PDF PubReader ePub

Purpose
Dexamethasone is a mainstay antiemetic regimen for the prevention of chemotherapy-induced nausea and vomiting. The aim of this pilot study was to assess the incidence of and factors associated with steroid-induced diabetes in cancer patients receiving chemotherapy with dexamethasone as an antiemetic.
Materials and Methods
Non-diabetic patients with newly diagnosed gastrointestinal cancer who received at least three cycles of highly or moderately emetogenic chemotherapy with dexamethasone as an antiemetic were enrolled. Fasting plasma glucose levels, 2-hour postprandial glucose levels, and hemoglobin A1C tests for the diagnosis of diabetes were performed before chemotherapy and at 3 and 6 months after the start of chemotherapy. The homeostasis model assessment of insulin resistance (HOMA-IR) was used as an index for measurement of insulin resistance, defined as a HOMA-IR ≥ 2.5.
Results
Between January 2012 and November 2013, 101 patients with no history of diabetes underwent laboratory tests for assessment of eligibility; 77 of these patients were included in the analysis. Forty-five patients (58.4%) were insulin resistant and 17 (22.1%) developed steroid-induced diabetes at 3 or 6 months after the first chemotherapy, which included dexamethasone as an antiemetic. Multivariate analysis showed significant association of the incidence of steroid-induced diabetes with the cumulative dose of dexamethasone (p=0.049).
Conclusion
We suggest that development of steroid-induced diabetes after antiemetic dexamethasone therapy occurs in approximately 20% of non-diabetic cancer patients; this is particularly significant for patients receiving high doses of dexamethasone.

Citations

Citations to this article as recorded by

Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura, Hitoshi Arioka, Hirotoshi Iihara, Mitsuhiro Sugawara, Hajime Morita, Ayako Mochizuki, Shuichi Nawata, Keisuke Mishima, Ayako Tsuboya, Tempei Miyaji, Kazunori Honda, Ayako Yokomizo, Naoya Hashimoto, Takes
British Journal of Cancer.2024; 130(2): 224. CrossRef
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
Daiki Tsuji, Shigeru Nakagaki, Itsuki Yonezawa, Kenichi Suzuki, Takashi Yokokawa, Yohei Kawasaki, Takumi Yamaguchi, Takashi Kawaguchi, Masahiro Hatori, Takuma Matsumoto, Yukio Sakata, Keisuke Yamamoto, Tomoyasu Nishimura, Yuki Kogure, Toshinobu Hayashi, M
Investigational New Drugs.2024; 42(1): 44. CrossRef
Change in abdominal obesity after colon cancer surgery – effects of left-sided and right-sided colonic resection
Younes Kays Mohammed Ali, Troels Gammeltoft Dolin, Janus Damm Nybing, Jakob Lykke, Frederik Hvid Linden, Erik Høgh-Schmidt, Thorkild I. A. Sørensen, Jesper Frank Christensen, Yousef J. W. Nielsen, Jim Stenfatt Larsen, Sten Madsbad, Julia Sidenius Johansen
International Journal of Obesity.2024; 48(4): 533. CrossRef
Dexamethasone-Free Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy: A Double-Blind, Phase III Randomized Controlled Trial (CINV POD study)
Venkatraman Radhakrishnan, Kritthivasan Venkatakrishnan, Jayachandran Perumal Kalaiyarasi, Gangothri Selvarajan, Nizamudin Mahaboobasha, Paulson Vijaykumar Victor, Malarvizhi Anbazhagan, Deyva Manohari Sivanandam, Swaminathan Rajaraman
JCO Global Oncology.2024;[Epub] CrossRef
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Jung-Hwan Cho, Sunghwan Suh
Endocrinology and Metabolism.2024; 39(2): 222. CrossRef
The impact of surgery and oncological treatment on risk of type 2 diabetes onset in patients with colorectal cancer: nationwide cohort study in Denmark
Caroline Krag, Maria Saur Svane, Sten Madsbad, Susanne Boel Graversen, Jesper Frank Christensen, Thorkild IA Sørensen, Louise Lang Lehrskov, Tinne Laurberg
eLife.2024;[Epub] CrossRef
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Jap
Ayako Yokomizo, Kazuhisa Nakashima, Arisa Iba, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-Il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako Eguchi N
International Journal of Clinical Oncology.2024; 29(11): 1632. CrossRef
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clin
Kazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako
International Journal of Clinical Oncology.2024; 29(12): 1785. CrossRef
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric Oncology
Rupert Bartsch, Daniel Aletaha, Thorsten Fuereder, Matti Aapro, Francois R. Jornayvaz, Pierre-Olivier Lang, Denis Migliorini, Chantal Csajka, Marie-Bernadette Aretin, Vérène Dougoud-Chauvin
Journal of Geriatric Oncology.2024; : 102077. CrossRef
Diabetes and cancer: Optimising glycaemic control
Nalinie Joharatnam‐Hogan, Daniel L. Morganstein
Journal of Human Nutrition and Dietetics.2023; 36(2): 504. CrossRef
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
Scientific Reports.2023;[Epub] CrossRef
Diabetes and cancer co-management: patient-reported challenges, needs, and priorities
Laura C. Pinheiro, Jacklyn Cho, Julia Rothman, Caroline Zeng, Micayla Wilson, Lisa M. Kern, Rulla M. Tamimi, Monika M. Safford
Supportive Care in Cancer.2023;[Epub] CrossRef
Link between Blood Cell-Associated Inflammatory Indices and Chemotherapy-Induced Hyperglycemia in Women Affected with Breast Cancer: Clinical Studies
Krishna Prasad, Suresh Rao, Sanath Kumar Hegde, Thomas George, Rhea Katherine D'souza, Sucharitha Suresh, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2023; 12(02): 118. CrossRef
Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer
Dana Mahin, Sayeh Moazami Lavasani, Leon Cristobal, Niki Tank Patel, Mina Sedrak, Daphne Stewart, James Waisman, Yuan Yuan, Wai Yu, Raynald Samoa, Nora Ruel, Susan E. Yost, Hayley Lee, Sung Hee Kil, Joanne E. Mortimer
Journal of Clinical Medicine.2023; 12(5): 1906. CrossRef
Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study
Vinod Sharma, Akash Kumar, Annie Baa, Sudhir Kirar, Atul Sharma, Sameer Bakhshi, Ajay Gogia, Prabhat Singh Malik, Sameer Rastogi, Atul Batra, Deepam Pushpam, Babita Kataria, Hari Sagiraju, Aparna Sharma, Vishwajeet Singh
BMJ Supportive & Palliative Care.2023; 13(e3): e867. CrossRef
Identifying patients with diabetes in a day‐case systemic anti‐cancer therapy population: the Belfast Regional Oncology Centre experience
Adam Waterworth, Ashleigh Hamilton, Philip Johnston, Anna Todd, Grainne Connolly, Ailish Nugent, Paula Scullin, Sarah McKenna, Sarah Lawless, Helen Wallace, Ian Wallace
Practical Diabetes.2023; 40(3): 26. CrossRef
Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the prevention of chemotherapy-induced nausea and vomiting in older patients (>65 years) fit for cisplatin: A sub-analysis from a phase 3 study
Luigi Celio, Rupert Bartsch, Matti Aapro
Journal of Geriatric Oncology.2023; 14(6): 101537. CrossRef
Effects of Vitamin Intake on Blood Glucose in Cancer Patients Undergoing Chemotherapy: Quantitative and Descriptive Research
Ji Yeong Kim, Kyung Hee Lim
Korean Journal of Adult Nursing.2023; 35(2): 148. CrossRef
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy
Toshinobu Hayashi, Mototsugu Shimokawa, Koichi Matsuo, Masanobu Uchiyama, Kei Kawada, Takafumi Nakano, Takashi Egawa
Oncology.2023; 101(9): 584. CrossRef
Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer
Krishna Prasad, Sanath Hegde, Suresh Rao, Rhea Katherine D'souza, Thomas George, Manjeshwar Shrinath Baliga, Sucharitha Suresh
South Asian Journal of Cancer.2023;[Epub] CrossRef
Prognostic Factors for Hyperglycemia in Patients Receiving Chemotherapy
Jiyeong Kim, Kyung Hee Lim
Cancer Nursing.2023;[Epub] CrossRef
COVID‐19 and dexamethasone‐induced hyperglycaemia: Workload implications for diabetes inpatient teams
Younes R. Younes, Susan Stockley, Lorna Keegan, Linda O’Donoghue, Elizabeth Yohannan, Liz Read, Jamie‐Leigh Williamson, John Peter, Kavitha Lakshmipathy, Vera Smout, Vidhu Nayyar, Julian Emmanuel, Sunil Zachariah, James Clark, Benjamin C. T. Field
Diabetic Medicine.2022;[Epub] CrossRef
The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
Mengjun Liang, Liping Xiong, Aihua Li, Jiafan Zhou, Yajuan Huang, Miaofang Huang, Xing Zhang, Hongrui Shi, Ning Su, Yi Wei, Zongpei Jiang
BMC Nephrology.2022;[Epub] CrossRef
Insulin resistance and weight gain in women treated for early stage breast cancer
Grace Makari-Judson, Richard Viskochil, Deborah Katz, Ruth Barham, Wilson C. Mertens
Breast Cancer Research and Treatment.2022; 194(2): 423. CrossRef
Cytoprotective effect of genistein against dexamethasone-induced pancreatic β-cell apoptosis
Kanchana Suksri, Namoiy Semprasert, Thawornchai Limjindaporn, Pa-thai Yenchitsomanus, Sirirat Kooptiwoot, Suwattanee Kooptiwut
Scientific Reports.2022;[Epub] CrossRef
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
BMC Cancer.2022;[Epub] CrossRef
Efficacy of the Dexamethasone-Sparing Triplet Regimen for Preventing Cisplatin-Induced Emesis: a Combined Analysis
Luigi Celio, Erminio Bonizzoni, Elena Montani, Matti Aapro
Future Oncology.2022; 18(30): 3389. CrossRef
How should rheumatologists manage glucocorticoid-induced hyperglycemia?
Hiroyuki Nakamura, Yuichiro Fujieda, Akinobu Nakamura, Tatsuya Atsumi
Modern Rheumatology.2021; 31(3): 519. CrossRef
A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy
Koung Jin Suh, Seonghae Yoon, Jin Won Kim, Seo Hyun Yoon, Ji-Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jee Hyun Kim
Journal of Geriatric Oncology.2021; 12(6): 922. CrossRef
Incidence and disease course of new-onset diabetes mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective multicenter cohort study
Eun Kyung Lee, Bokyung Koo, Yul Hwangbo, You Jin Lee, Ji Yeon Baek, Yong Jun Cha, Sun Young Kim, Sung Hoon Sim, Keun Seok Lee, In Hae Park, Hyewon Lee, Jungnam Joo, Sujeong Go, Seung Chul Heo, Min Kyong Moon
Diabetes Research and Clinical Practice.2021; 174: 108751. CrossRef
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study
Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, Luigi Cavanna, Olga Martelli, Simona Carnio, Elena Collovà, Federica Bertolini, Fausto Petrelli, Alessandra Cassano, Rita Chiari, Francesca Zanelli, Salvatore Pisconti, Isabella Vittimberga, Antonietta
The Oncologist.2021; 26(10): e1854. CrossRef
Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations
Fei Chen, Lanting Hao, Shiheng Zhu, Xinyuan Yang, Wenhao Shi, Kai Zheng, Tenger Wang, Huiran Chen
Infectious Diseases and Therapy.2021; 10(4): 1907. CrossRef
Glycemic Excursion, Adverse Drug Reactions, and Self-Management in Diabetes Patients Undergoing Chemotherapy: A Literature Review
Naoko Terao, Kumi Suzuki
Asia-Pacific Journal of Oncology Nursing.2021; 8(6): 610. CrossRef
Patient-Centered Diabetes Care of Cancer Patients
Anupam Kotwal, Yee-Ming M. Cheung, Grace Cromwell, Andjela Drincic, Houry Leblebjian, Zoe Quandt, Robert J. Rushakoff, Marie E. McDonnell
Current Diabetes Reports.2021;[Epub] CrossRef
Quercetin modulates hyperglycemia by improving the pancreatic antioxidant status and enzymes activities linked with glucose metabolism in type 2 diabetes model of rats: In silico studies of molecular interaction of quercetin with hexokinase and catalase
Sunday O. Oyedemi, Godswill Nwaogu, Chika I. Chukwuma, Olaoluwa T. Adeyemi, Motlalepula G. Matsabisa, Shasank S. Swain, Olayinka A. Aiyegoro
Journal of Food Biochemistry.2020;[Epub] CrossRef
Side Effects of Adjuvant Chemotherapy and their Impact on Outcome in Elderly Breast Cancer Patients: A Cohort Study
Valentina Zanuso, Vittorio Fregoni, Lorenzo Gervaso
Future Science OA.2020;[Epub] CrossRef
Incidence of Hyperglycemia/Secondary Diabetes in Women who have Undergone Curative Chemotherapy for Breast Cancer: First Study from India
Suresh Rao, Krishna Prasad, Soniya Abraham, Thomas George, Supreeth Kakkaje Chandran, Manjeshwar Shrinath Baliga
South Asian Journal of Cancer.2020; 09(03): 130. CrossRef
Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes
Moein Ala, Razieh Mohammad Jafari, Ahmad Reza Dehpour
Current Diabetes Reviews.2020; 16(9): 984. CrossRef
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin
Hiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, Tempei Miyaji, Kazuhiro Shimomura, Honda Kazunori, Hirotoshi Iihara, Yasushi Ohno, Yusuke Inada, Hitoshi Arioka, Hajime Morita, Naoya Hida, Mitsuhiro Sugawara, Chikatoshi Katada, Shuichi Nawata, Hiroo Ish
BMJ Open.2020; 10(12): e041737. CrossRef
Effect of high-dose dexamethasone on patients without diabetes during elective neurosurgery: a prospective study
Majid Alabbood, Min Ling, Kenneth Ho
Diabetology International.2019; 10(2): 109. CrossRef
Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma
Saby George, Brian I. Rini, Hans J. Hammers
JAMA Oncology.2019; 5(3): 411. CrossRef
GLUCOSE EXCHANGE DISORDERS IN PATIENTS TAKING GLUCOCORTICOSTEROIDS: FEATURES OF CLINICAL MANIFESTATIONS AND CORRECTION
Al’bert Yu. Selimov, Lyudmila N. Eliseeva, Valeriya P. Kurinnaya, Sergei P. Oranskii
Kuban Scientific Medical Bulletin.2019; 26(1): 209. CrossRef
Steroid-induced diabetes in cancer patients
Gemma Dinn
Journal of Prescribing Practice.2019; 1(12): 610. CrossRef
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes
Allison Grimes, Ashraf Mohamed, Jenna Sopfe, Rachel Hill, Jane Lynch
JNCI Monographs.2019; 2019(54): 132. CrossRef
Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
Luigi Celio, Erminio Bonizzoni, Emma Zattarin, Paolo Codega, Filippo de Braud, Matti Aapro
BMC Cancer.2019;[Epub] CrossRef
Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy
Yuka Ito, Takashi Tsuda, Hiroko Minatogawa, Sayaka Kano, Kentaro Sakamaki, Masahiko Ando, Koichiro Tsugawa, Yasuyuki Kojima, Naoki Furuya, Kunihiro Matsuzaki, Mamoru Fukuda, Sadatoshi Sugae, Ichiro Ohta, Hitoshi Arioka, Yutaka Tokuda, Kazutaka Narui, Ayak
Journal of Clinical Oncology.2018; 36(10): 1000. CrossRef
Glucocorticoid‐induced diabetes among people without diabetes: a literature review
Majid Alabbood, Min Ling, Kenneth Ho
Practical Diabetes.2018; 35(2): 63. CrossRef
Metformin prevents metabolic side effects during systemic glucocorticoid treatment
Eleonora Seelig, Stefanie Meyer, Katharina Timper, Nicole Nigro, Martina Bally, Ida Pernicova, Philipp Schuetz, Beat Müller, Marta Korbonits, Mirjam Christ-Crain
European Journal of Endocrinology.2017; 176(3): 349. CrossRef
Central pancreatectomy: an oncologically safe option to treat metastases of other neoplasms of the mid-portion of the pancreas?
Traian Dumitrascu, Andra Scarlat, Mihnea Ionescu, Irinel Popescu
Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(2): 76. CrossRef
Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids
Jennifer Vidler, Charlotte Rogers, Deborah Yallop, Stephen Devereux, Ellinor Wellving, Orla Stewart, Alison Cox, Katharine F. Hunt, Shireen Kassam
Journal of Clinical & Translational Endocrinology.2017; 9: 18. CrossRef
Consumption of Fresh Yellow Onion Ameliorates Hyperglycemia and Insulin Resistance in Breast Cancer Patients During Doxorubicin-Based Chemotherapy: A Randomized Controlled Clinical Trial
Farnaz Jafarpour-Sadegh, Vahid Montazeri, Ali Adili, Ali Esfehani, Mohammad-Reza Rashidi, Saeed Pirouzpanah
Integrative Cancer Therapies.2017; 16(3): 276. CrossRef

14,503 View
352 Download
46 Web of Science
51 Crossref

First
Prev
Page of 1
Next
Last

Search